Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
Clinical trial NCT05681390 · UNKNOWN
Trial details
- NCT number
- NCT05681390
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-01
- Primary completion
- 2024-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.